PTC Therapeutics Inc. (NASDAQ:PTCT)’s share price was up 4.8% during mid-day trading on Friday . The stock traded as high as $8.24 and last traded at $8.10, with a volume of 1,558,510 shares trading hands. The stock had previously closed at $7.73.

Several equities analysts have issued reports on PTCT shares. Cowen and Company reiterated a “hold” rating on shares of PTC Therapeutics in a research report on Sunday, April 17th. Credit Suisse Group AG reiterated a “buy” rating on shares of PTC Therapeutics in a research report on Friday, May 6th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $9.00 price objective on shares of PTC Therapeutics in a research report on Monday, April 18th. Jefferies Group reiterated a “hold” rating and issued a $8.00 price objective on shares of PTC Therapeutics in a research report on Friday, May 6th. Finally, Wedbush reiterated a “neutral” rating and issued a $12.00 price objective on shares of PTC Therapeutics in a research report on Wednesday, July 20th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and two have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $34.72.

The company’s 50 day moving average price is $6.93 and its 200-day moving average price is $9.61. The company’s market capitalization is $276.75 million.

PTC Therapeutics (NASDAQ:PTCT) last issued its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.27) by $0.13. The company had revenue of $15.40 million for the quarter, compared to analyst estimates of $15.24 million. During the same period in the prior year, the company earned ($1.14) EPS. The company’s quarterly revenue was up 150.0% compared to the same quarter last year. Analysts expect that PTC Therapeutics Inc. will post ($4.95) EPS for the current fiscal year.

Several large investors have modified their holdings of the stock. Westfield Capital Management Co. LP increased its stake in shares of PTC Therapeutics by 49.6% in the fourth quarter. Westfield Capital Management Co. LP now owns 1,872,220 shares of the biopharmaceutical company’s stock worth $60,660,000 after buying an additional 621,079 shares in the last quarter. BlackRock Advisors LLC increased its stake in shares of PTC Therapeutics by 2.3% in the fourth quarter. BlackRock Advisors LLC now owns 505,966 shares of the biopharmaceutical company’s stock worth $16,393,000 after buying an additional 11,568 shares in the last quarter. Jennison Associates LLC increased its stake in shares of PTC Therapeutics by 5.9% in the fourth quarter. Jennison Associates LLC now owns 1,023,987 shares of the biopharmaceutical company’s stock worth $33,177,000 after buying an additional 57,092 shares in the last quarter. Marshall Wace LLP increased its stake in shares of PTC Therapeutics by 50.6% in the fourth quarter. Marshall Wace LLP now owns 44,410 shares of the biopharmaceutical company’s stock worth $1,439,000 after buying an additional 14,926 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in shares of PTC Therapeutics by 8.1% in the fourth quarter. Rhumbline Advisers now owns 33,247 shares of the biopharmaceutical company’s stock worth $1,077,000 after buying an additional 2,485 shares in the last quarter.

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company’s lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.